Clinical Trial Update: SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on SGI-110 (guadecitabine) in adults with untreated acute myeloid leukemia who are not candidates for intensive remission inductio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• SGI-110 (guadecitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Leukemia, Myeloid, Acute | Phase 3 | Status: COMPLETED | Results posted: 2021-01-14